Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01802073 · ClinicalTrials.gov registry record · Phase 3
Primary Sclerosing Cholangitis With Oral Vancomycin by the Study of Its Antimicrobial and Immunomodulating Effects
A Phase 3 study of Primary Sclerosing Cholangitis, sponsored by Stanford University.
- Completed
- Registry status
- Phase 3
- Development phase
- 34
- Enrollment target
- 1
- Study location
NCT01802073: Completed Phase 3 study of Primary Sclerosing Cholangitis, sponsored by Stanford University.
NCT01802073 is a Phase 3 study of Primary Sclerosing Cholangitis that has completed, run by Stanford University. The registered enrollment target is 34 participants, below the 551-participant average among 23 other Primary Sclerosing Cholangitis trials with a reported enrollment target (94% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01802073, a Phase 3 study of Primary Sclerosing Cholangitis, has completed, sponsored by Stanford University.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 34 participants
- Enrollment target
- 1
- Study location
Study Summary
Determine the benefit of oral vancomycin therapy for Primary Sclerosing Cholangitis.
Primary Outcome
Clinically significant improvement was determined by investigator assessment per participant based on their medical history and disease stage. Elevated ALT was any value greater than the upper limit of the standard reference range used by patient's laboratory.
Conditions Studied
Interventions
- DRUG Oral Vancomycin
Study Locations (1)
California
- Stanford University Medical Center - Palo Alto
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 34 participants |
| Start Date | 2012-01 |
| Est. Completion | 2015-08 |
| Phase | Phase 3 |
What the finished NCT01802073 record still lists
NCT01802073 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 34 participants, a relatively small participant target, below the 551-participant average among 23 other Primary Sclerosing Cholangitis trials with a reported enrollment target (94% lower).
The record links to 1 condition, with Primary Sclerosing Cholangitis appearing as the primary indexed condition, and to 1 intervention - of which Oral Vancomycin is the first listed.
NCT01802073 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT01802073 about?
NCT01802073 is a clinical study titled "Primary Sclerosing Cholangitis With Oral Vancomycin by the Study of Its Antimicrobial and Immunomodulating Effects". Determine the benefit of oral vancomycin therapy for Primary Sclerosing Cholangitis.
What is the current status of trial NCT01802073?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 34 participants. The study started on 2012-01. Estimated completion is 2015-08.
What conditions does trial NCT01802073 study?
This clinical trial studies the following conditions: Primary Sclerosing Cholangitis.
What interventions are being tested in trial NCT01802073?
The interventions under investigation include: Oral Vancomycin (DRUG).
Who is sponsoring clinical trial NCT01802073?
This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01802073 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Primary Sclerosing Cholangitis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01802073's enrollment target sits among peer trials
34 15th of 23 higher than 9 of 23 other Primary Sclerosing Cholangitis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Primary Sclerosing Cholangitis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Pharmacologic Approaches to Preventing Primary Sclerosing Cholangitis Recurrence After Liver Transplantation
RECRUITING · Phase 2
-
MRI Biomarkers in as Predictor of Clinical Endpoints in Pediatric Autoimmune Liver Disease
RECRUITING
-
MRI Based Biomarkers in Pediatric Autoimmune Liver Disease
RECRUITING
-
A-LiNK: Improving Outcomes in Autoimmune Liver Disease
RECRUITING
-
Statin Therapy in Primary Sclerosing Cholangitis (PSC): a Multi-omics Study
RECRUITING · Early Phase 1
-
Characterization of Biliary Cell-derived Organoids From Bile of PSC and Non-PSC Patients
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02897063 · 34 participants · Phase 1
Effects of Midodrine and Droxidopa on Splanchnic Capacitance in Autonomic Failure
- NCT03906617 · 34 participants · Phase 4
Bupivacaine/Epinephrine +Dexamethasone vs. Liposomal Bupivacaine
- NCT03992378 · 34 participants · NA
Neuromodulation to Regulate Inflammation and Autonomic Imbalance in Sepsis
- NCT04047849 · 34 participants · Phase 4
Latency Antibiotics in Previable PPROM, 18 0/7- 22 6/7 WGA
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia